Xipamide
Based on 1 Customer Validation
Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na+/Cl--potassium transporter inhibitor with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl-/NaCO3- anion exchanger, and increases calcium reabsorption while promoting potassium and magnesium excretion. Xipamide is mainly cleared via the renal pathway and causes a temporary decrease in glomerular filtration rate under specific conditions. Xipamide does not affect Ca2+ signaling induced by endothelin-1 and other factors, nor does it inhibit various ion cotransport or pump activities in red blood cells. Xipamide can be used in researches related to cardiovascular diseases, hypertension (especially with left ventricular hypertrophy), advanced renal failure, and liver cirrhosis with ascites.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.74%
- CAS No.: 14293-44-8
- Formule: C15H15ClN2O4S
- Masse moléculaire:354.81
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Xipamide (0.1-100 μM; 3-15 min) maximally inhibits amiloride-induced cell acidification by 50% at 1 μM (after 15 min preincubation) in rat heart myogenic H9c2 cells, an effect that is dependent on extracellular HCO3− and sensitive to DIDS[2].
Xipamide (10-5-10-3 M; 90 min) potently inhibits the (NaCO3−/Cl−) anion exchanger in fresh human red blood cells with an IC50 of 2.5 × 10-5 M, making it the most active anion carrier inhibitor among the tested diuretics[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 14293-44-8
-
Appearance Solid
-
Masse moléculaire 354.81
-
Formule C15H15ClN2O4S
-
Color White to off-white
-
SMILES
O=C(NC1=C(C)C=CC=C1C)C2=CC(S(=O)(N)=O)=C(Cl)C=C2O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvant et solubilité
DMSO : 250 mg/mL (704.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8184 mL | 14.0920 mL | 28.1841 mL | 70.4602 mL |
| 5 mM | 0.5637 mL | 2.8184 mL | 5.6368 mL | 14.0920 mL | |
| 10 mM | 0.2818 mL | 1.4092 mL | 2.8184 mL | 7.0460 mL | |
| 15 mM | 0.1879 mL | 0.9395 mL | 1.8789 mL | 4.6973 mL | |
| 20 mM | 0.1409 mL | 0.7046 mL | 1.4092 mL | 3.5230 mL | |
| 25 mM | 0.1127 mL | 0.5637 mL | 1.1274 mL | 2.8184 mL | |
| 30 mM | 0.0939 mL | 0.4697 mL | 0.9395 mL | 2.3487 mL | |
| 40 mM | 0.0705 mL | 0.3523 mL | 0.7046 mL | 1.7615 mL | |
| 50 mM | 0.0564 mL | 0.2818 mL | 0.5637 mL | 1.4092 mL | |
| 60 mM | 0.0470 mL | 0.2349 mL | 0.4697 mL | 1.1743 mL | |
| 80 mM | 0.0352 mL | 0.1762 mL | 0.3523 mL | 0.8808 mL | |
| 100 mM | 0.0282 mL | 0.1409 mL | 0.2818 mL | 0.7046 mL |
Xipamide Related Classifications
HY-W042301 Related Classifications
Powered by Bioz
- Xipamide
- 14293-44-8
- Anion Exchangers
- Carbonic Anhydrase
- Endothelin Receptor
- renal failure
- left ventricular hypertrophy
- rat heart myogenic H9c2 cells
- carbonic anhydrase
- cardiovascular diseases
- Na+/Cl?-Kotransporter
- newborn rat cardiomyocytes
- liver cirrhosis with ascites
- human red blood cells
- hypertension
- Inhibitor
- inhibitor
- inhibit